Search - tctmd.com

Displaying 81 - 100 of 130

Sort: Relevancy | Date

News Conference News EAS 2020

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Michael O'Riordan

October 07, 2020

News Daily News

Cholesterol Guidelines Fail Young MI Patients Who Might Have Benefited From Statins

L.A. McKeown

August 04, 2020

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

News Daily News

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Yael L. Maxwell

April 28, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

News Daily News

Pricey, Unproven ‘Executive’ CVD Screening the Norm at Top US Hospitals

Michael O'Riordan

January 16, 2020

News Daily News

Higher Chili Pepper Consumption Linked to Fewer CVD Deaths

L.A. McKeown

December 17, 2019

News Daily News

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

Yael L. Maxwell

December 12, 2019

News Daily News

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Michael O'Riordan

December 03, 2019

News Conference News AHA 2019

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

Caitlin E. Cox

November 19, 2019

News Conference News AHA 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Yael L. Maxwell

November 16, 2019

News Daily News

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Michael O'Riordan

November 11, 2019

News Daily News

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Yael L. Maxwell

October 22, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Michael O'Riordan

July 01, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

Advertisement

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Cholesterol Guidelines Fail Young MI Patients Who Might Have Benefited From Statins

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Pricey, Unproven ‘Executive’ CVD Screening the Norm at Top US Hospitals

Higher Chili Pepper Consumption Linked to Fewer CVD Deaths

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content